Diagnostics

Matthew Nowland

Vice President, Regulatory Affairs, Diagnostics

Relying on more than 20 years of success, Mr. Nowland helps sponsors to optimize regulatory strategy as they seek to bring new diagnostics to market. He has helped companies from venture capital backed start-ups to large global entities, to develop and advance innovative technologies, including molecular diagnostics, medical devices, surgical robotics, and blood products.

Mr. Nowland has firsthand experience working within biotech, device, and diagnostics companies to develop and oversee pre- and post-approval activities in areas including, but not limited to, oncology, neurology, cardiology, inflammation, and infectious disease. Under Mr. Nowland’s leadership, Premier supports diagnostics developers with strategic planning, regulatory strategy, process improvement, risk mitigation and quality assurance, clinical monitoring, and regulatory submissions.